Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Global Crispr Genomic Cure Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
6.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
6.2.3. By Delivery Method (In vivo, Ex vivo)
6.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
6.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
6.2.6. By Region
6.2.7. By Company (2022)
6.3. Product Market Map
6.3.1. By Disease Type
6.3.2. By Therapy Type
6.3.3. By Delivery Method
6.3.4. By End User
6.3.5. By Targeted Genetic Modification
6.3.6. By Region
7. North America Crispr Genomic Cure Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
7.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
7.2.3. By Delivery Method (In vivo, Ex vivo)
7.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
7.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
7.2.6. By Country
7.3. North America: Country Analysis
7.3.1. United States Crispr Genomic Cure Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Therapy Type
7.3.1.2.3. By Delivery Method
7.3.1.2.4. By End User
7.3.1.2.5. By Targeted Genetic Modification
7.3.2. Canada Crispr Genomic Cure Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Therapy Type
7.3.2.2.3. By Delivery Method
7.3.2.2.4. By End User
7.3.2.2.5. By Targeted Genetic Modification
7.3.3. Mexico Crispr Genomic Cure Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Therapy Type
7.3.3.2.3. By Delivery Method
7.3.3.2.4. By End User
7.3.3.2.5. By Targeted Genetic Modification
8. Europe Crispr Genomic Cure Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
8.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
8.2.3. By Delivery Method (In vivo, Ex vivo)
8.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
8.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
8.2.6. By Country
8.3. Europe: Country Analysis
8.3.1. Germany Crispr Genomic Cure Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Therapy Type
8.3.1.2.3. By Delivery Method
8.3.1.2.4. By End User
8.3.1.2.5. By Targeted Genetic Modification
8.3.2. United Kingdom Crispr Genomic Cure Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Therapy Type
8.3.2.2.3. By Delivery Method
8.3.2.2.4. By End User
8.3.2.2.5. By Targeted Genetic Modification
8.3.3. France Crispr Genomic Cure Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Therapy Type
8.3.3.2.3. By Delivery Method
8.3.3.2.4. By End User
8.3.3.2.5. By Targeted Genetic Modification
8.3.4. Italy Crispr Genomic Cure Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease Type
8.3.4.2.2. By Therapy Type
8.3.4.2.3. By Delivery Method
8.3.4.2.4. By End User
8.3.4.2.5. By Targeted Genetic Modification
8.3.5. Spain Crispr Genomic Cure Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease Type
8.3.5.2.2. By Therapy Type
8.3.5.2.3. By Delivery Method
8.3.5.2.4. By End User
8.3.5.2.5. By Targeted Genetic Modification
9. Asia-Pacific Crispr Genomic Cure Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
9.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
9.2.3. By Delivery Method (In vivo, Ex vivo)
9.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
9.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
9.2.6. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Crispr Genomic Cure Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Therapy Type
9.3.1.2.3. By Delivery Method
9.3.1.2.4. By End User
9.3.1.2.5. By Targeted Genetic Modification
9.3.2. Japan Crispr Genomic Cure Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Therapy Type
9.3.2.2.3. By Delivery Method
9.3.2.2.4. By End User
9.3.2.2.5. By Targeted Genetic Modification
9.3.3. India Crispr Genomic Cure Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Therapy Type
9.3.3.2.3. By Delivery Method
9.3.3.2.4. By End User
9.3.3.2.5. By Targeted Genetic Modification
9.3.4. Australia Crispr Genomic Cure Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Disease Type
9.3.4.2.2. By Therapy Type
9.3.4.2.3. By Delivery Method
9.3.4.2.4. By End User
9.3.4.2.5. By Targeted Genetic Modification
9.3.5. South Korea Crispr Genomic Cure Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Disease Type
9.3.5.2.2. By Therapy Type
9.3.5.2.3. By Delivery Method
9.3.5.2.4. By End User
9.3.5.2.5. By Targeted Genetic Modification
10. South America Crispr Genomic Cure Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
10.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
10.2.3. By Delivery Method (In vivo, Ex vivo)
10.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
10.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Crispr Genomic Cure Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease Type
10.3.1.2.2. By Therapy Type
10.3.1.2.3. By Delivery Method
10.3.1.2.4. By End User
10.3.1.2.5. By Targeted Genetic Modification
10.3.2. Argentina Crispr Genomic Cure Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease Type
10.3.2.2.2. By Therapy Type
10.3.2.2.3. By Delivery Method
10.3.2.2.4. By End User
10.3.2.2.5. By Targeted Genetic Modification
10.3.3. Colombia Crispr Genomic Cure Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease Type
10.3.3.2.2. By Therapy Type
10.3.3.2.3. By Delivery Method
10.3.3.2.4. By End User
10.3.3.2.5. By Targeted Genetic Modification
11. Middle East and Africa Crispr Genomic Cure Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
11.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
11.2.3. By Delivery Method (In vivo, Ex vivo)
11.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
11.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
11.2.6. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Crispr Genomic Cure Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Disease Type
11.3.1.2.2. By Therapy Type
11.3.1.2.3. By Delivery Method
11.3.1.2.4. By End User
11.3.1.2.5. By Targeted Genetic Modification
11.3.2. Saudi Arabia Crispr Genomic Cure Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Disease Type
11.3.2.2.2. By Therapy Type
11.3.2.2.3. By Delivery Method
11.3.2.2.4. By End User
11.3.2.2.5. By Targeted Genetic Modification
11.3.3. UAE Crispr Genomic Cure Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Disease Type
11.3.3.2.2. By Therapy Type
11.3.3.2.3. By Delivery Method
11.3.3.2.4. By End User
11.3.3.2.5. By Targeted Genetic Modification
11.3.4. Kuwait Crispr Genomic Cure Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Disease Type
11.3.4.2.2. By Therapy Type
11.3.4.2.3. By Delivery Method
11.3.4.2.4. By End User
11.3.4.2.5. By Targeted Genetic Modification
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Development
13.2. Mergers & Acquisitions
13.3. Product Launches
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Business Overview
15.2. Product Offerings
15.3. Recent Developments
15.4. Financials (As Reported)
15.5. Key Personnel
15.6. SWOT Analysis
15.6.1. Merck KGaA
15.6.2. Takara Bio Inc
15.6.3. Lonza Group AG
15.6.4. Horizon Discovery Group Ltd
15.6.5. Genscript Biotech Corp
15.6.6. Synthego Corp
15.6.7. Precision BioSciences Inc
15.6.8. Mammoth Biosciences Inc
15.6.9. Thermo Fisher Scientific Inc
15.6.10. Intellia Therapeutics Inc
16. Strategic Recommendations
17. About Us & Disclaimer